

DRUG DELIVERY SYSTEMS USING QUANTUM COMPUTING



Edited By

Rishabha Malviya

Sonali Sundram

Dhanalekshmi Unnikrishnan Meenakshi

 **Scrivener
Publishing**

WILEY

Drug Delivery Systems Using Quantum Computing

Scrivener Publishing

100 Cummings Center, Suite 541J
Beverly, MA 01915-6106

Publishers at Scrivener

Martin Scrivener (martin@scrivenerpublishing.com)
Phillip Carmical (pcarmical@scrivenerpublishing.com)

Drug Delivery Systems Using Quantum Computing

Edited by

Rishabha Malviya

School of Medical and Allied Sciences, Galgotias University, India

Sonali Sundram

School of Medical and Allied Sciences, Galgotias University, India

and

Dhanalekshmi Unnikrishnan Meenakshi

*College of Pharmacy, National University of Science and Technology, Muscat,
Sultanate of Oman*



WILEY

This edition first published 2024 by John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, USA and Scrivener Publishing LLC, 100 Cummings Center, Suite 541J, Beverly, MA 01915, USA

© 2024 Scrivener Publishing LLC

For more information about Scrivener publications please visit www.scrivenerpublishing.com.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, except as permitted by law. Advice on how to obtain permission to reuse material from this title is available at <http://www.wiley.com/go/permissions>.

Wiley Global Headquarters

111 River Street, Hoboken, NJ 07030, USA

For details of our global editorial offices, customer services, and more information about Wiley products visit us at www.wiley.com.

Limit of Liability/Disclaimer of Warranty

While the publisher and authors have used their best efforts in preparing this work, they make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives, written sales materials, or promotional statements for this work. The fact that an organization, website, or product is referred to in this work as a citation and/or potential source of further information does not mean that the publisher and authors endorse the information or services the organization, website, or product may provide or recommendations it may make. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for your situation. You should consult with a specialist where appropriate. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read.

Library of Congress Cataloging-in-Publication Data

ISBN 978-1-394-15914-7

Cover image: Pixabay.Com

Cover design by Russell Richardson

Set in size of 11pt and Minion Pro by Manila Typesetting Company, Makati, Philippines

Printed in the USA

10 9 8 7 6 5 4 3 2 1

*Dear healthcare professionals,
We are dedicating this book to you. Our love for the profession
shall live forever.*

Contents

Foreword	xxi
Preface	xxiii
Acknowledgments	xxv
1 Quantum Computational Concepts and Approaches in Drug Discovery, Development and Delivery	1
<i>Dhanalekshmi Unnikrishnan Meenakshi, Suresh Manic Kesavan, Arul Prakash Francis and Shah Alam Khan</i>	
1.1 Introduction	2
1.2 Algorithms and QC in Pharma	4
1.2.1 Algorithms	4
1.2.2 Supervised Learning	4
1.2.3 Unsupervised Learning	5
1.2.4 Multi-Task Neural Networks	6
1.2.5 Graph Convolution	6
1.3 Potential of QC in Drug Discovery	6
1.3.1 Target Recognition and Validation	8
1.3.2 Production and Validation of Hits	8
1.3.3 Lead Optimization	8
1.3.4 Clinical Trials	8
1.3.5 Linking and Generating Data	9
1.4 QC and Drug Delivery	9
1.5 QC in Drug Delivery Modalities	12
1.5.1 Computational Approach Towards Nano Particulate Drug Delivery	14
1.5.2 Computational Approach for Bone Drug Delivery	14
1.5.3 Computational Approach for Polymeric Drug Delivery	15
1.5.4 Computational Approach for Microsphere Drug Delivery	15
	vii

1.5.5	Computational Approach for Dendrimer-Based Drug Delivery	16
1.5.6	Computational Approach for Carbon Nanotube-Based Drug Delivery	17
1.6	QC Applications in Pharma Industry	18
1.7	Challenges or Prospects	20
1.8	Conclusion	21
	References	21
2	Quantum-Enabled Drug Discovery Process	27
	<i>Abhishek Rao, Deepika Kumari, Satyendra Singh, Ketan Kumar and Vijay Kumar Prajapati</i>	
2.1	Introduction	28
2.2	Usual Challenges in Drug Designing and Discovery	29
2.2.1	Commercial Challenge	31
2.2.2	Modification or Transitional Challenges	31
2.2.3	Unexplored Areas Under Classical Computational Techniques	32
2.3	Medicinal Chemistry Through Quantum Mechanics	32
2.3.1	Underappreciation of Chemical Interactions in Protein–Ligand Complexes	33
2.3.2	Non-Classical Hydrogen Bonding	33
2.3.3	π – π Stacking	34
2.3.4	Hydrophobic Bond Interactions	34
2.3.5	Coordination from Water	35
2.3.6	Explicit Water	35
2.3.7	Implicit Water	35
2.4	Interaction Analysis	36
2.4.1	Fragment Interaction Energy	36
2.4.2	Binding Free Energy	36
2.4.3	Fragment Molecular Orbital (FMO) Process and Analysis	37
2.5	Geometric Optimization	39
2.5.1	Analyzing Gradients	39
2.6	GAMESS: A Computational Technique for Biochemical Simulations	40
2.6.1	Introduction to Biochemical Simulations	40
2.6.2	Parametrizing Quantum Mechanics Method for Simulations	41
2.6.3	Quantum Mechanics and Molecular Mechanics Associated with GAMESS	41

2.6.4	Introduction to QuanPol	44
2.6.5	QuanPol: Covalent Boundary Treatment	45
2.6.6	GO and Harmonic Vibration Frequency	46
2.6.7	Molecular Dynamics Simulation	46
2.6.8	Free Energy Perturbation (Deviation of Energy) Simulation	46
2.6.8.1	QuanPol Process Umbrella Sampling	47
2.6.8.2	QuanPol Process Thermodynamic Integration (TI)	47
2.6.9	Setting Up Valuation and Calculation	48
2.6.10	Molecular Modeling and Visualization Software	48
2.7	Conclusion	51
	References	52
3	Quantum Computing and Its Promise in Drug Discovery	57
	<i>Rakhi Mishra, Prem Shankar Mishra, Rupa Mazumder, Avijit Mazumder and Shruti Varshney</i>	
3.1	Introduction	58
3.1.1	Need for Quantum Computing	60
3.2	Quantum Computing's Types, Applications, Generality, and Power	61
3.2.1	Quantum Annealer	61
3.2.2	Analog Quantum	62
3.2.3	Universal Quantum	63
3.3	Drug Discovery and Quantum Computing	64
3.3.1	A Brief History of Drug Discovery	64
3.3.2	Modern Drug Discovery	65
3.4	Role of Quantum Computing in Drug Discovery	65
3.5	Quantum Computing Methodology in Drug Discovery	66
3.5.1	Target Identification and Validation	67
3.5.2	Hit Generation and Validation	68
3.5.3	Lead Optimization	68
3.5.4	Data Linkage and Generation	69
3.5.5	Clinical Trials	69
3.5.6	Molecular Formations	69
3.6	Examples of Companies Using Quantum Theory to Accelerate Drug Discovery	71
3.6.1	Aqemia	72
3.6.2	Hafnium Labs	72
3.6.3	Kuano	73

3.6.4	Menten AI	73
3.6.5	Pharmacelera	74
3.6.6	PharmCADD	74
3.6.7	Polaris Quantum Biotech	75
3.6.8	ProteinQure	75
3.6.9	Riverlane	76
3.6.10	Roivant Discovery	76
3.6.11	XtalPi	77
3.6.12	Zapata Computing	77
3.7	Advantages of Quantum Computing	78
3.8	Applications of Quantum Computing in Drug Discovery and Development	79
3.8.1	A Future View of QC and Drug Discovery	80
3.8.2	Current Developments in QC and Drug Discovery	80
3.9	Conclusion	82
	References	83
4	Exploring Nano-Based Therapeutics by Quantum Computational Modeling	93
	<i>Ponduri Teja Kumar, Roja Rani Budha, G. Raghavendra Kumar, B. Nagamani and G.S.N. Koteswara Rao</i>	
4.1	Introduction to Nano-Based Therapeutics	94
4.2	Introduction to Quantum Computational Modeling with Respect to Nano-Based Therapeutics	99
4.2.1	Particle-Based Models	99
4.2.2	Continuum-Based Models	103
4.3	Exploration of Nano-Based Therapeutics	105
4.4	Design and Development of Nano-Based Therapeutics	109
4.4.1	Prediction of Solubility	109
4.4.2	Prediction of Permeability	110
4.4.3	Selection of Components and Optimization of Formulation of Nano-Based Therapeutics	113
4.4.3.1	Prediction of Therapeutic Loading	114
4.4.4	Prediction of Therapeutic Release or Leakage	115
4.4.5	Prediction of the Pharmacokinetic Profile of Nano-Based Therapeutics	116
4.4.5.1	Prediction of Absorption	117
4.4.5.2	Prediction of Distribution (Protein Corona Formation)	117
4.4.5.3	Prediction of Metabolism	119
4.4.5.4	Prediction of Excretion	119

4.4.6	Understanding Protein Corona Formation	120
4.4.7	Understanding the Interaction of Nanosized Carrying Objects with Bio-Membranes	122
4.4.8	Prediction of the Pharmacodynamic Profile of Nano-Based Therapeutics	123
4.4.9	Prediction of Adverse Drug Reactions and Nanotoxicity	124
4.4.10	Design of Target-Oriented Nano-Based Therapeutics	125
4.5	Conclusion	127
	References	128
5	Application of Quantum Computational Simulation in Drug Delivery Strategies with Carbon Nanotubes	141
	<i>Rupali Sharma, Yashomita Mehta, Shekhar Sharma, Jagriti Narang and Shabnam Thakur</i>	
5.1	Introduction	142
5.2	Properties of CNTs	144
5.2.1	Electrical Properties of CNTs	144
5.2.2	Elastro-Mechanical Properties of CNTs	145
5.2.3	Thermal Properties of CNTs	145
5.2.4	Optical Properties of CNTs	146
5.3	Functionalization of CNTs	146
5.3.1	Covalent Functionalization	146
5.3.2	Noncovalent Functionalization of CNTs	147
5.3.3	Encapsulation Inside CNTs	148
5.3.4	“Defect” Functionalization	148
5.4	Significance of CNT in Drug Delivery	149
5.5	Overview of CNT-Based Drug Delivery	150
5.6	Pharmacokinetics of CNTs	150
5.6.1	Absorption	151
5.6.2	Distribution	151
5.6.3	Metabolism and Excretion	152
5.7	Biosafety of Carbon Nanotube	152
5.7.1	Mechanism of CNT Toxicity	153
5.7.2	Scenario to Bypass Carbon Nanotube Toxicity	153
5.8	Quantum Computational	154
5.8.1	Structure-Based Drug Design Methods (SBDD)	154
5.8.2	Ligand-Based Drug Design Methods (LBDD)	155
5.9	Various Simulation Approaches in Drug-CNTs Interaction	156
5.9.1	QM Approaches	157

5.9.1.1	<i>Ab Initio</i> Approach	159
5.9.1.2	Semiempirical Approach	159
5.9.1.3	Hartree–Fock (HF) Approach	159
5.9.2	Molecular Dynamics (MD) Approaches	159
5.9.3	Monte Carlo (MC) Simulation Approaches	160
5.9.4	Hybrid Approaches	160
5.9.4.1	MD and QM Approaches	160
5.9.4.2	MM and QM Approaches	161
5.10	Applications of Quantum Computational Methods	161
5.10.1	Applications of Quantum Computational Methods in DDS	161
5.10.2	Applications of Quantum Computational Methods in Nanobiosensors	165
5.11	Conclusion	165
	References	166
6	Quantum Computation Approach for Nanotechnology-Based Targeted Drug Delivery Systems	171
	<i>Smriti Ojha, Sudhanshu Mishra, Anubhav Anand, Amrita Singh and Palak Gupta</i>	
6.1	Introduction	172
6.2	The Types of Quantum Computers	174
6.2.1	Scalable Quantum Computers	174
6.2.2	Noisy Intermediate-Scale Quantum Devices	174
6.2.3	Analog Quantum Devices	175
6.3	Role of QC in Computer-Aided Drug Design	175
6.4	Development of Molecular Formulations	177
6.4.1	QC-Based Development of Nanocarriers	178
6.4.2	QC in Biosensor	181
6.4.3	QC-Based Targeted Drug Delivery	182
6.4.4	Target Identification	183
6.4.5	Target Validation	185
6.4.6	Identification of Hit and Its Validation	185
6.4.7	Optimization of Lead	186
6.5	Data Generation, Interpretation, and Co-Relation	186
6.6	Role of QC in Clinical Trials	187
6.7	Future Prospects	187
6.8	Conclusion	187
	References	188

7	Role of Quantum Computing Simulations in Targeted Drug Delivery of Liposomes	195
	<i>Rupali Sharma, Suman Khurana, Arun Mittal, Parveen Kumar Goyal, Kavita Sangwan and Satish Sardana</i>	
7.1	Introduction	196
7.2	Liposomes	198
7.3	Liposome Classification	199
	7.3.1 Based on Preparation Methods	199
	7.3.2 Based on Compositional and Structural Characteristics	199
7.4	Methods of Liposome Preparation	199
7.5	Drug Loading Method	200
	7.5.1 Passive Loading Technique	200
	7.5.1.1 Sonication	200
	7.5.1.2 French Pressure Cell	201
	7.5.1.3 Freeze-Thawed Liposomes	201
	7.5.1.4 Solvent Evaporation with Ether Injection	201
	7.5.1.5 Alcohol Infusion	201
	7.5.1.6 Method of Reverse Phase Evaporation	201
	7.5.1.7 Removal of Non-Encapsulated Material with Detergent	202
	7.5.2 Active Loading Technique	202
	7.5.2.1 Pro-Liposome	202
	7.5.2.2 Lyophilization	202
7.6	Newer Approaches to Liposomes	202
	7.6.1 Stealth Liposomes (Improving Circulation Time)	203
	7.6.2 Improving Elasticity (Transferosomes)	204
	7.6.3 Ethosomes (Improving Skin Penetration)	204
	7.6.4 Pharmacosomes (Improvement in Medication Delivery for Poorly Soluble Medicines)	204
	7.6.5 Nebulized Liposomes and Stimuli-Responsive Liposomes	205
7.7	Quantum Computing	205
7.8	Computational Modeling for Drug Delivery Process	207
7.9	Correlation Between Quantum Computing Simulation and Targeted Delivery of Liposomes	208
7.10	Computational Simulation of Lipid Membranes	210
7.11	Properties Measured by Simulation	210
	7.11.1 Mechanical and Structural Properties	210
	7.11.2 Dynamic Properties	211

7.11.3	Molecule Permeation	211
7.12	Liposomal Drug Delivery System	212
7.13	Experimental Techniques and Role of Computational Simulation in Liposomal Drug Delivery System	213
7.13.1	Lipids Membrane	214
7.13.2	Size, Surface Charge, and Zeta Potential	216
7.13.3	Morphology and Lamellarity	217
7.14	Computational Simulation Study of Liposomes	217
7.15	Conclusion	220
	References	221
8	Quantum Computational Methods and Computer-Aided Drug Design in Transdermal Drug Delivery of Nanoparticles	231
	<i>Jahasultana Mohammed, Haritha Lanka, Roja Rani Budha, Rajasekhar Reddy Alavala, G.S.N. Koteswara Rao and Surya Kovvasu</i>	
8.1	Introduction	232
8.2	Skin Lipid Membranes for TDD	234
8.3	Computer-Aided Drug Designing for Formulation	236
8.4	Advantages of CADD	236
8.5	System and Model	236
8.5.1	Force Field	236
8.5.2	Software Supporting MD and Visualization	238
8.6	Computational Components	238
8.7	Procedure	238
8.7.1	Framework for <i>In Silico</i> NP Design	238
8.7.2	Integumentary Model	239
8.7.3	NP Model	240
8.7.4	Free Permeability Energy	240
8.8	Testing, Co-Delivery of Actives, and Active Screening	241
8.9	Future Challenges	241
8.10	Conclusion	242
	References	242
9	Computational Approaches for Drug Delivery of Nanoparticles	247
	<i>Urvashi Sharma, Hemant Khambete, Nitu Singh, Sanjay Jain, Neelam Jain and Kamal Dua</i>	
9.1	Drug Delivery System	248
9.1.1	Conventional vs. Controlled Drug Delivery Systems	249
9.1.2	History of DDS Development	251
9.1.3	Drug Delivery Routes	255

9.2	Nanoparticles	258
9.2.1	Need for Developing NPs	259
9.2.2	Advantages	259
9.2.3	Classification of NPs	260
9.3	Problems in Conventional Manufacturing of NPs	263
9.4	Computational Drug Delivery	267
9.4.1	Computational Approach for Nanoparticulate Drug Delivery	268
9.4.2	Computational Approach for Bone Drug Delivery	270
9.4.3	Computational Approach for Nasal Drug Delivery	270
9.4.4	Computational Approach for Polymeric Drug Delivery	270
9.4.5	Computational Approach for Microsphere Drug Delivery	271
9.4.6	Computational Approach for Liposomal Drug Delivery	271
9.4.7	Computational Approach for Tumor Cord Drug Delivery	271
9.4.8	Computational Approach for Gastroretentive Drug Delivery	272
9.4.9	Computational Approach for Bioerodible Device-Based Drug Delivery	272
9.5	Future Prospects	273
9.6	Conclusion	273
9.7	Acknowledgement	274
9.8	Funding Information	274
	References	274
10	Utilization of Computational Methods for Rational Development of Nanoemulsions, Polymeric Micelles, and Dendrimers Drug Delivery Systems	283
	<i>Swarupanjali Padhi and Rupa Mazumder</i>	
10.1	Introduction	284
10.2	Recognizing Optimal Drug-Excipient Pairs	285
10.3	Emerging of Nano-Formulation Using Theoretic Technique	286
10.3.1	Theoretical Approach	286
10.3.1.1	Solubility Parameter	286
10.3.1.2	Assessment of Total SP	288
10.3.1.3	Flory-Huggins (FH) Theory	291
10.4	Influence of Rigidity, Conformation, and Compatibility on Drug Loading	297

10.5	MD Simulations and Docking	298
10.5.1	Molecular Dynamics (MD)	298
10.6	Solubility	299
10.6.1	Free Energy Perturbation Calculations	301
10.6.2	Widom Insertion Method	301
10.7	Screening	302
10.7.1	Carriers-Oriented Screening	302
10.7.2	Drugs-Oriented Screening	303
10.7.3	Interactions Imaging	304
10.8	Artificial Intelligence and Machine Learning	305
10.9	Partition Coefficient	306
10.9.1	Prediction of Partition Coefficient Using Density Functional Theory (DFT)	308
10.9.2	Prediction of Partition Coefficient Using MD Simulations	309
10.10	Machine Learning	312
10.11	Conclusion	316
	References	317
11	Molecular Simulation: A Promising Tool for <i>In Silico</i> Design of Drug Delivery Formulations	325
	<i>Prem Shankar Mishra, Rakhi Mishra and Deepika Sharma</i>	
11.1	Introduction	326
11.1.1	Simulation of Molecular Dynamic	327
11.1.2	A Molecular Simulations Using a General System	328
11.2	Software Available for Performing MDs	330
11.3	Applications of Molecular Simulation in Drug Delivery System	333
11.3.1	Lipid Bilayer Drug Diffusion and Penetration	333
11.3.2	Solubility of Drugs	334
11.3.3	Carrier-Drug Miscibility	334
11.3.4	Drug Crystallization	335
11.3.5	Drug Loading and Release	336
11.4	Molecular Dynamics Simulations for Nanomedical Applications	338
11.5	Molecular Dynamics Insight Examples	340
11.5.1	Bloodstream Behavior and Coronal Protective Polymer	340
11.5.2	Controlled Release and Drug Loading	341
11.6	Conclusion	342
	References	342

12 Controlling the Drug Release Rate and Targeted Drug Delivery to the Desired Site by Molecular Simulation	353
<i>Deepika Bairagee, Sunita Panchawat, Neelam Jain and Sirisha Pingali</i>	
Abbreviations	354
12.1 Introduction	355
12.1.1 MC and MD Processes	357
12.1.2 Correlation of Continual Methods with Molecular Simulation	358
12.1.3 Simulation Scheme	359
12.1.4 Comparison Between MC and MD Processes	361
12.1.5 Size and Boundary Conditions of the System	362
12.1.6 Coarse-Graining	363
12.1.7 Free Energy Calculation	364
12.1.8 Force Fields	365
12.1.9 Simulation Software	368
12.2 MD Simulations: Existing Limits	368
12.3 MD Simulation and Drug Discovery	370
12.4 Applications in Drug Discovery	371
12.4.1 Drug Diffusion and Lipid Bilayer Permeation	371
12.4.2 Drug Solubility	372
12.4.3 Carrier-Drug Miscibility	372
12.4.4 Drug Crystallization	373
12.4.5 Drug Loading and Release	373
12.5 Molecular Simulation of Drug Delivery Strategies with Dendrimer	374
12.6 Molecular Simulation of Drug Delivery Strategies with Polymer	375
12.7 Liposome-Based Molecular Simulation of Drug Delivery Strategies	377
12.8 Molecular Simulation of Drug Delivery Strategies with Carbon Nanotube	379
12.9 Conclusion	381
Acknowledgment	383
Funding	383
References	383

13 Molecular Docking: An Essential Step in Computer-Aided Drug Design	389
<i>Lata Potey, Suchita Waghmare, Anshu Chaudhary Dudhe, Rupesh Dudhe and Prafulla Sabale</i>	
13.1 Introduction	390
13.1.1 Medicinal Chemistry	390
13.1.2 Computer-Aided Drug Design (CADD) and Molecular Docking	391
13.1.3 History and Progression of CADD	392
13.1.4 Classification of CADD	393
13.1.4.1 Structure-Based Drug Design (SBDD)	393
13.1.4.2 Ligand-Based Drug Design (LBDD)	394
13.1.5 Application of CADD in Drug Discovery and Development	394
13.1.6 Stages of Drug Discovery	395
13.1.6.1 Identification of Target	396
13.1.6.2 Target Validation	396
13.1.6.3 Identification of Lead	397
13.1.6.4 Lead Optimization	398
13.1.6.5 Product Characterization	399
13.1.6.6 Preclinical Testing	399
13.1.6.7 The Investigational New Drug (IND) Process	400
13.1.6.8 Clinical Research	400
13.2 Conclusion	403
References	404
14 Challenges and Emerging Problems in CADD	407
<i>Akshita Arora, Simranjeet Kaur and Amandeep Singh</i>	
14.1 Introduction	408
14.1.1 The Antiquity of CADD	408
14.2 Preamble of CADD	408
14.2.1 Structure-Based Drug Design	409
14.2.2 Protein Structure Preparation	409
14.2.3 Binding Site Identification	409
14.2.4 Molecular Docking	410
14.2.5 Scoring Functions	410
14.3 Ligand-Based Drug Design	410
14.4 Challenges	410
14.4.1 Challenges in CAD (Computer-Aided Design)	410
14.4.2 Geometry	411

14.4.2.1	Controlling Shape	411
14.4.2.2	Interoperability	411
14.4.2.3	Design Exploration	412
14.4.3	Interactive Techniques	413
14.4.3.1	Reverse Engineering	413
14.4.3.2	Everything in Its Place	413
14.4.3.3	What We Do	414
14.4.4	Scale	415
14.4.4.1	Understanding Vast Quantities of Data	415
14.4.4.2	Suitable Layout for Users	415
14.4.4.3	Retrieving Data Years Later	416
14.4.4.4	Constricted by the Light Speed	416
14.5	Challenges in CADD (Computer-Aided Drug Design)	417
14.5.1	Metal-Binding Docking	417
14.5.2	Protein-Protein Docking	418
14.5.3	Evaluation of Protein-Ligand Flexibility and Interaction	418
14.5.4	Protein-Ligand Docking	418
14.5.5	Docking Peptides or Peptide-Like Ligands	420
14.5.6	Water Solvation and Docking	420
14.5.7	Covalent Docking	421
14.5.7.1	Bigger QM Regions	422
14.5.7.2	Utilization of Polarizable Force Fields and Polarized Embedding	422
14.5.7.3	Improvements on the QM Level	423
14.5.8	Pose vs. Scoring	423
14.5.9	Chemical Space	424
14.5.10	Biological Space	424
14.6	Future Prospects of CADD	425
14.6.1	Molecular Dynamics Simulations	426
14.6.2	Virtual Screening	427
14.6.3	Density Functional Theory (DFT)	428
14.6.4	Drug Design-Related Web Servers	429
14.6.5	Big Data	431
14.6.6	Quantum Mechanics (QM)	432
14.7	Recent Patents in CADD	433
14.8	Conclusion	437
	References	438
	Index	443

Foreword

The origin of this unique book started in a conversation I had with Rishabha about ten years ago. He had just started his career in research and wished to make a contribution to pharmacy professionals. I knew he was going to be a star in his field as he had all the qualities of a high-flyer. Every story and every achievement were a performance. Today, I am writing this Foreword for his dream project.

Identifying and developing small molecules and macromolecules that might help cure illnesses and diseases is the core activity of pharmaceutical companies. Given its focus on molecular formations, the pharmaceutical industry is a natural candidate for quantum computing. Today's trendiest issues in technology are all related to quantum computing. Thanks to technology, computing issues that were once thought to be insurmountable are now being solved by individuals and businesses. This technology has had a substantial impact on many different domains, including healthcare, the pharmaceutical industry, drug discovery, and many more.

The development of this emerging technology, both by itself and in concert with other technologies, has the potential to make a significantly positive impact on society. The impact of quantum computing on the pharmaceutical industry relies on the development, manufacture, and delivery of molecules. This book explains the profound impact that quantum computing could have on the pharmaceutical industry and presents user examples of its application. I hope after reading this book, healthcare professionals and pharmaceutical companies will be well-advised to assess the quantum computing opportunity for themselves and begin laying the groundwork for securing their place in this new competitive and technological landscape.

Dr. Kamla Pathak

Dean and Professor
Faculty of Pharmacy

Uttar Pradesh University of Medical Sciences
Saifai, Etawah
Uttar Pradesh, India

Preface

The majority of drug candidates have low solubility, rapid blood clearance, poor targeting, and, usually, poor ability to penetrate cell membranes. Some of these obstacles can be addressed by drug delivery systems (DDSs) that improve drug delivery to the site of action. Drug delivery technology is advancing significantly, and controlling the precise level and/or location of a given drug in the body reduces adverse effects, lowers dosages, and makes new therapies possible.

Nevertheless, there are still significant obstacles to delivering certain medications to particular cells. Drug delivery methods change pharmacokinetic, pharmacodynamic, and drug release patterns to enhance product efficacy and safety, as well as patient convenience and compliance. Computational approaches in drug development enable quick screening of a vast chemical library and identification of possible binders by using modeling, simulation, and visualization tools. Quantum computing (QC) is a fundamentally new computing paradigm based on quantum mechanics rules that enables certain computations to be conducted significantly more rapidly and effectively than regular computing, and hence this has huge promise for the pharmaceutical sector.

Significant advances in computational simulation are making it easier to comprehend the process of drug delivery. This book explores an important biophysical component of DDSs, and how computer modelling may help with the logical design of DDSs with enhanced and optimized characteristics. The book concentrates on computational research for various important types of nanocarriers, including dendrimers and dendrons, polymers, peptides, nucleic acids, lipids, carbon-based DDSs, and gold nanoparticles.

This new technology's advancement promises a significant and positive effect on society, both independently and in conjunction with existing technologies. With ethical research, development, and implementation, the trickle-down consequences of the quantum revolution should enhance

the lives of many people. Understanding the effects that quantum computing could have on the pharmaceutical business is therefore crucial.

This book contains 14 chapters, written by top researchers from many parts of the world. The book is profusely referenced and copiously illustrated, and all chapters were deliberately reviewed and revised to meet the highest standard of publication. We are deeply grateful to everyone who helped with this book and greatly appreciate the dedicated support and valuable assistance rendered by Martin Scrivener and the Scrivener Publishing team during its publication.

The Editors

April 2024

Acknowledgments

Writing a book seemed difficult, but working on this had been a delightful experience. It was more rewarding and motivating than I had imagined. I would like to begin by expressing my gratitude to the Almighty, whose unending blessings and supreme power enable us to accomplish all our goals.

Although this period of my life was filled with many ups and downs, I am eternally grateful to my family for their continuous support and encouragement that made it possible to complete this task.

I am deeply indebted to the management at Galgotias University. I want to thank you all for letting me serve, for being a part of our amazing organization, and for motivating me every day.

Many thanks to all contributors. Without their participation, this goal could not have been achieved. Last but not least, I would like to thank our publisher for their support, innovative suggestions, and guidance in bringing out this edition.

Quantum Computational Concepts and Approaches in Drug Discovery, Development and Delivery

Dhanalekshmi Unnikrishnan Meenakshi^{1*}, Suresh Manic Kesavan²,
Arul Prakash Francis³ and Shah Alam Khan^{1†}

¹*College of Pharmacy, National University of Science and Technology,
Muscat, Oman*

²*College of Engineering, National University of Science and Technology,
Muscat, Oman*

³*Centre of Molecular Medicine and Diagnostics (COMMAND), Saveetha Dental
College and Hospitals, Saveetha Institute of Medical and Technical Sciences,
Saveetha University, Chennai, India*

Abstract

The use of quantum computing approaches in drug discovery, development, and delivery is on rise. Quantum computing (QC) is becoming more popular as a cost-saving measure in the research, production, and manufacturing of drugs. The use of molecular dynamics and computation tasks has greatly enhanced drug design and optimization of drug delivery systems. This QC method aids in investigating several issues that are difficult to examine in laboratory studies. This chapter discusses how QC simulations can assign a specific drug target site by anticipating the target, resulting in a successful drug development process. It also highlights the important applications of several algorithms in drug delivery and disease diagnosis. Additionally, computational methodologies for various drug delivery systems and carriers are discussed. This chapter also discusses ongoing challenges in the pharmaceutical industry and concerns regarding the chances of accomplishment of QC concepts and technology.

*Corresponding author: dhanalekshmi@nu.edu.om

†Corresponding author: shahalam@nu.edu.om

Keywords: Drug discovery, drug delivery, quantum computing, simulations, optimization, molecular dynamics, algorithms

1.1 Introduction

Drug development and discovery to identify new chemical entities to treat or cure human diseases is a very long, complex, expensive, and tedious process that often fails [1]. Over the years, the scientific community has tried its best to decrease expenditure, speed up the process of drug development, and progress the accomplishment frequency of identifying drugs or molecules of natural or synthetic origin [2, 3]. In the late 20th century, the paradigm slowly shifted from Ethnopharmacology, a traditional discovery method from medicinal plants, to a computational chemistry-based technique called computer-aided drug design (CADD) to identify a lead molecule capable of binding to a target protein to exhibit favorable therapeutic effects and pharmacokinetic profile [4]. Discovery and optimization of lead molecules following the high-throughput screening (HTS) over hit libraries using a CADD approach can be done either by structured-based or ligand-based drug design [5]. While the latter is favored in the absence of target architectural data and uses a quantitative structure–activity relation (QSAR) model, the former approach is used when knowledge of the 3D structural information of the biological target is available for molecular docking (pharmacophore modeling). Although most of the drugs in the pipeline have been discovered using CADD, the higher computational cost to study the molecular dynamics of protein–ligand interactions and the reliability of the current statistical techniques available to study pharmacokinetic profile limits its usefulness [6–8]. The challenges and limitations of CADD could be overcome with the help of an emerging quantum computing (QC) technology that can handle and stimulate larger and more complex chemical structures more efficiently. QC application will certainly benefit the pharmaceutical industry from innovation in drug discovery to the manufacture and development of promising therapeutic modalities [8].

Constructing a new drug for a chronic illness in the medical context was mainly based on new pills. Various drugs for identifying energetic facets in conventional therapies like penicillin have recently been developed. In natural compounds, organic molecules that aid in medical purposes to discover ingredients such as cells or unbroken life forms are used in pharmaceutical manufacturing. This is known as traditional pharmacology. As the DNA sequence has enabled massive cloning techniques and improved protein refinement, HTS with various libraries has become